Back to News
Market Impact: 0.3
Belite Bio Announces NDA Submission In Japan For Tinlarebant Under Sakigake Designation
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Belite Bio submitted a New Drug Application in Japan for tinlarebant to treat Stargardt disease type 1. The drug has received Japan's SAKIGAKE designation, enabling an accelerated regulatory review process and potentially improving the timeline to commercialization in the market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
BLTE0.72
More News
- Microsoft breaks Patch Tuesday record with 974-CVE deluge
- Stock Movers: Chime, Stryker, Compass Pathways (Podcast)
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- UK announces new Israel sanctions, despite U.S. warning of economic consequences
- Pharma major plummets over 10% after third trial disappointment in a week
- Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026